{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:08:48Z","timestamp":1785780528654,"version":"3.56.0"},"reference-count":465,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) arise due to acquired somatic driver mutations in stem cells and develop over 10\u201330 years from the earliest cancer stages (essential thrombocythemia, polycythemia vera) towards the advanced myelofibrosis stage with bone marrow failure. The JAK2V617F mutation is the most prevalent driver mutation. Chronic inflammation is considered to be a major pathogenetic player, both as a trigger of MPN development and as a driver of disease progression. Chronic inflammation in MPNs is characterized by persistent connective tissue remodeling, which leads to organ dysfunction and ultimately, organ failure, due to excessive accumulation of extracellular matrix (ECM). Considering that MPNs are acquired clonal stem cell diseases developing in an inflammatory microenvironment in which the hematopoietic cell populations are progressively replaced by stromal proliferation\u2014\u201ca wound that never heals\u201d\u2014we herein aim to provide a comprehensive review of previous promising research in the field of circulating ECM fragments in the diagnosis, treatment and monitoring of MPNs. We address the rationales and highlight new perspectives for the use of circulating ECM protein fragments as biologically plausible, noninvasive disease markers in the management of MPNs.<\/jats:p>","DOI":"10.3390\/cancers15174323","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T10:09:49Z","timestamp":1693390189000},"page":"4323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Junker","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3099","authenticated-orcid":false,"given":"Trine A.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy, Herlev Hospital, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy, Herlev Hospital, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-7307","authenticated-orcid":false,"given":"Christina","family":"Jensen","sequence":"additional","affiliation":[{"name":"Nordic Bioscience A\/S, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[{"name":"Nordic Bioscience A\/S, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Willumsen","sequence":"additional","affiliation":[{"name":"Nordic Bioscience A\/S, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"ref_2","first-page":"895","article-title":"Myeloproliferative Neoplasms","volume":"377","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Skov, V. (2020). Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses. Cancers, 12.","DOI":"10.3390\/cancers12082194"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1038\/bcj.2016.75","article-title":"Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing","volume":"6","author":"Angona","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kj\u00e6r, L. (2020). Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12082100"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2021","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijcard.2022.06.029","article-title":"Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"364","author":"Solli","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.14019","article-title":"High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"111","author":"Solli","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: Connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression and Symptoms","volume":"14","author":"Blackmon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nasillo, V., Riva, G., Paolini, A., Forghieri, F., Roncati, L., Lusenti, B., Maccaferri, M., Messerotti, A., Pioli, V., and Gilioli, A. (2021). Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041906"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(15)00092-7","article-title":"Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: A population-based cohort study","volume":"2","author":"Frederiksen","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis","volume":"94","author":"Pettersson","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Brabrand, M., and Frederiksen, H. (2020). Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers, 12.","DOI":"10.3390\/cancers12103061"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cumbo, C., Anelli, L., Zagaria, A., Coccaro, N., Tarantini, F., Specchia, G., Musto, P., and Albano, F. (2022). Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063177"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ejh.12437","article-title":"Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"94","author":"Hasselbalch","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m, M.O., Hasselbalch, H.C., and Andersen, M.H. (2020). Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12071763"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Liisborg, C., Hasselbalch, H.C., and S\u00f8rensen, T.L. (2020). Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12030573"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25763","DOI":"10.18632\/aging.203803","article-title":"Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system","volume":"13","author":"Liisborg","year":"2021","journal-title":"Aging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.eclinm.2020.100526","article-title":"Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration","volume":"26","author":"Liisborg","year":"2020","journal-title":"Eclinicalmedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.eclinm.2021.101248","article-title":"Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation","volume":"43","author":"Liisborg","year":"2022","journal-title":"Eclinicalmedicine"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liisborg, C., Skov, V., Kj\u00e6r, L., Hasselbalch, H.C., and S\u00f8rensen, T.L. (2022). Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269960"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/aos.15247","article-title":"Age-related macular degeneration and myeloproliferative neoplasms\u2014A common pathway","volume":"100","author":"Liisborg","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjh.12581","article-title":"Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study","volume":"163","author":"Farmer","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428194.2020.1817437","article-title":"Highly increased risk of fracture in patients with myeloproliferative neoplasm","volume":"62","author":"Johansson","year":"2021","journal-title":"Leuk. Lymphoma."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12185-015-1803-3","article-title":"Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: A cross-sectional study using DXA, HR-pQCT, and bone turnover markers","volume":"102","author":"Farmer","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/17474086.2015.1053456","article-title":"Bone morbidity in chronic myeloproliferative neoplasms","volume":"8","author":"Farmer","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00198-015-3412-7","article-title":"Polycythemia is associated with bone loss and reduced osteoblast activity in mice","volume":"27","author":"Oikonomidou","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00198-016-3788-z","article-title":"Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera","volume":"28","author":"Farmer","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"929498","DOI":"10.3389\/fonc.2022.929498","article-title":"Inhibition of Osteoblast Differentiation by JAK2V617F Megakaryocytes Derived from Male Mice with Primary Myelofibrosis","volume":"12","author":"Karagianni","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood.2021011480","article-title":"Myeloproliferative disorders and their effects on bone homeostasis: The role of megakaryocytes","volume":"139","author":"Karagianni","year":"2022","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4236\/ijcm.2013.412A1003","article-title":"The JAK2 V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study","volume":"4","author":"Kuriakose","year":"2013","journal-title":"Int. J. Clin. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bak, M., Jess, T., Flachs, E.M., Zwisler, A.-D., Juel, K., and Frederiksen, H. (2020). Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12092700"},{"key":"ref_54","first-page":"V09190483","article-title":"Myeloproliferative neoplasms and chronic inflammatory bowel disease","volume":"182","author":"Bak","year":"2020","journal-title":"Ugeskr Laeger."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.2011.147","article-title":"Myeloproliferative neoplasms cause glomerulopathy","volume":"80","author":"Said","year":"2011","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","article-title":"Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms","volume":"38","author":"Christensen","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.ajkd.2019.05.016","article-title":"Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy with Interstitial Extramedullary Hematopoiesis: A Case Report","volume":"74","author":"Maruyama","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.mbplus.2020.100034","article-title":"Calreticulin is important for the development of renal fibrosis and dysfunction in diabetic nephropathy","volume":"8","author":"Lu","year":"2020","journal-title":"Matrix Biol. Plus."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","article-title":"Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera","volume":"112","author":"Holik","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","article-title":"Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis","volume":"99","author":"Lucijanic","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00428-021-03129-y","article-title":"Renal post-mortem findings in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"479","author":"Person","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/his.14282","article-title":"Renal disease associated with myeloproliferative and myelodysplastic\/myeloproliferative neoplasia","volume":"78","author":"Sticht","year":"2021","journal-title":"Histopathology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gecht, J., Tsoukakis, I., Kricheldorf, K., Stegelmann, F., Klausmann, M., Griesshammer, M., Schulz, H., Hollburg, W., G\u00f6thert, J.R., and Sockel, K. (2021). Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Cancers, 13.","DOI":"10.3390\/cancers13164086"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ejh.13845","article-title":"Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11\u2009years follow-up","volume":"109","author":"Larsen","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41375-021-01382-3","article-title":"Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease","volume":"36","author":"Dawoud","year":"2022","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Fortes, M., Hern\u00e1ndez-Boluda, J.C., \u00c1lvarez-Larr\u00e1n, A., Raya, J.M., Angona, A., Estrada, N., Fox, L., Cuevas, B., Garc\u00eda-Hern\u00e1ndez, M.C., and G\u00f3mez-Casares, M.T. (2022). Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers, 14.","DOI":"10.3390\/cancers14092331"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/CLEP.S216787","article-title":"Vascular Diseases in Patients with Chronic Myeloproliferative Neoplasms\u2014Impact of Comorbidity","volume":"11","author":"Frederiksen","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Le Bousse-Kerdil\u00e8s, M.C. (2012). Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept. Fibrogenesis Tissue Repair., 5.","DOI":"10.1186\/1755-1536-5-S1-S20"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"415024","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis","volume":"2015","author":"Desterke","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"453020","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms","volume":"2015","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"869242","DOI":"10.1155\/2015\/869242","article-title":"Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms","volume":"2015","author":"Hoermann","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"145293","DOI":"10.1155\/2015\/145293","article-title":"Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"670580","DOI":"10.1155\/2015\/670580","article-title":"Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest","volume":"2015","author":"Mondet","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: Pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3389\/fimmu.2020.02093","article-title":"Remodeling the Bone Marrow Microenvironment\u2014A Proposal for Targeting Pro-inflammatory Contributors in MPN","volume":"11","author":"Jutzi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V55.3.383.383","article-title":"Urinary hydroxyproline excretion in myelofibrosis","volume":"55","author":"Wang","year":"1980","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.2830150405","article-title":"Increased serum procollagen III aminoterminal peptide in myelofibrosis","volume":"15","author":"Hochweiss","year":"1983","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2141.1983.tb01253.x","article-title":"Plasma fibronectin in myeloproliferative disorders and chronic granulocytic leukaemia","volume":"55","author":"Norfolk","year":"1983","journal-title":"Br. J. Haematol."},{"key":"ref_83","first-page":"2429","article-title":"Evolution des polyglobulies primitives vers la my\u00e9lofibrose. Surveillance par le dosage de l\u2019amino-propeptide du procollag\u00e8ne III [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide]","volume":"13","author":"Arrago","year":"1984","journal-title":"Presse Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1600-0609.1985.tb02827.x","article-title":"Serum procollagen III peptide in chronic myeloproliferative disorders","volume":"35","author":"Hasselbalch","year":"1985","journal-title":"Scand. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ajh.2830230204","article-title":"Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders","volume":"23","author":"Hasselbalch","year":"1986","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0609.1986.tb01736.x","article-title":"Type III aminoterminal propeptide of procollagen in some haematological malignancies","volume":"36","author":"Arrago","year":"1986","journal-title":"Scand. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2141.1986.tb07535.x","article-title":"Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis","volume":"63","author":"Alavaikko","year":"1986","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/00365518709168447","article-title":"Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders","volume":"47","author":"Hasselbalch","year":"1987","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1600-0609.1987.tb01454.x","article-title":"Urinary hydroxyproline excretion in the myelofibrosis-osteomyelosclerosis syndrome and related diseases","volume":"39","author":"Hasselbalch","year":"1987","journal-title":"Eur. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/jcp.40.12.1468","article-title":"Composition of immune complexes and their relation to plasma fibronectin in chronic myeloproliferative disorders","volume":"40","author":"Baglin","year":"1987","journal-title":"J. Clin. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.2830330105","article-title":"Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: Relation to disease activity and effect of chemotherapy","volume":"33","author":"Hasselbalch","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jcp.43.2.102","article-title":"Circulating high molecular weight IgG fibronectin complexes in myeloproliferative disorders","volume":"43","author":"Baglin","year":"1990","journal-title":"J. Clin. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.2830330216","article-title":"On the pathogenesis of angiogenesis in idiopathic myelofibrosis","volume":"33","author":"Hasselbalch","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0609.1990.tb00419.x","article-title":"Idiopathic myelofibrosis: A review","volume":"45","author":"Hasselbalch","year":"1990","journal-title":"Eur. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1699-0463.1991.tb05135.x","article-title":"Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study","volume":"99","author":"Lisse","year":"1991","journal-title":"APMIS"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.2830360102","article-title":"Circulating hyaluronan in the myelofibrosis\/osteomyelosclerosis syndrome and other myeloproliferative disorders","volume":"36","author":"Hasselbalch","year":"1991","journal-title":"Am. J. Hematol."},{"key":"ref_97","first-page":"39","article-title":"Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism","volume":"40","author":"Hasselbalch","year":"1993","journal-title":"Dan. Med. Bull."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2257.1995.tb00314.x","article-title":"Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis","volume":"17","author":"Reilly","year":"1995","journal-title":"Clin. Lab. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13547500902777608","article-title":"Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development","volume":"14","author":"Karsdal","year":"2009","journal-title":"Biomarkers"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinbiochem.2010.03.015","article-title":"Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers\u2014Are they the cause or the consequence of the disease?","volume":"43","author":"Karsdal","year":"2010","journal-title":"Clin. Biochem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/adt.2009.0258","article-title":"Macrophage-Mediated Proteolytic Remodeling of the Extracellular Matrix in Atherosclerosis Results in Neoepitopes: A Potential New Class of Biochemical Markers","volume":"8","author":"Barascuk","year":"2010","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/1354750X.2011.557440","article-title":"Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development","volume":"16","author":"Leeming","year":"2011","journal-title":"Biomarkers"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/adt.2012.474","article-title":"Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue Diseases Possibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure","volume":"11","author":"Karsdal","year":"2013","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fon.12.161","article-title":"Bringing cancer serological diagnosis to a new level: Focusing on HER2, protein ectodomain shedding and neoepitope technology","volume":"9","author":"Wang","year":"2013","journal-title":"Futur. Oncol."},{"key":"ref_105","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Willumsen, N., Bager, C.L., Leeming, D.J., Smith, V., Karsdal, M.A., Dornan, D., and Bay-Jensen, A.-C. (2013). Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-554"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cam4.303","article-title":"Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer","volume":"3","author":"Willumsen","year":"2014","journal-title":"Cancer Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/CBM-150520","article-title":"Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study","volume":"15","author":"Bager","year":"2015","journal-title":"Cancer Biomark."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Kristensen, J.H., Karsdal, M.A., Sand, J.M., Willumsen, N., Diefenbach, C., Svensson, B., H\u00e4gglund, P., and Oersnes-Leeming, D.J. (2015). Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0048-5"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.clinbiochem.2015.07.009","article-title":"Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders","volume":"48","author":"Kristensen","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.clinbiochem.2016.05.023","article-title":"Type VIII collagen is elevated in diseases associated with angiogenesis and vascular remodeling","volume":"49","author":"Hansen","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-16-0127","article-title":"Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study","volume":"25","author":"Bager","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2016.07.108","article-title":"Quantification of fibronectin as a method to assess ex vivo extracellular matrix remodeling","volume":"478","author":"Bager","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/14789450.2016.1134327","article-title":"Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: Understanding the extracellular matrix message and implication for current and future serological biomarkers","volume":"13","author":"Genovese","year":"2016","journal-title":"Expert Rev. Proteom."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neo.2017.01.008","article-title":"Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non\u2013Small Cell Lung Cancer","volume":"19","author":"Willumsen","year":"2017","journal-title":"Neoplasia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3892\/ol.2017.5900","article-title":"Unique insight into microenvironmental changes in colorectal cancer: Ex. vivo assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue","volume":"13","author":"Willumsen","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"52501","DOI":"10.18632\/oncotarget.15275","article-title":"Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancer","volume":"8","author":"Willumsen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kehlet, S., Bager, C., Willumsen, N., Dasgupta, B., Brodmerkel, C., Curran, M., Brix, S., Leeming, D., and Karsdal, M.A. (2017). Cathepsin-S degraded decorin are elevated in fibrotic lung disorders\u2014Development and biological validation of a new serum biomarker. BMC Pulm. Med., 17.","DOI":"10.1186\/s12890-017-0455-x"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-017-2074-z","article-title":"Quantification of altered tissue turnover in a liquid biopsy: A proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities","volume":"67","author":"Willumsen","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/15384047.2018.1480887","article-title":"A fragment of SPARC reflecting increased collagen affinity shows pathological relevance in lung cancer\u2014Implications of a new collagen chaperone function of SPARC","volume":"19","author":"Kehlet","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Kehlet, S.N., Willumsen, N., Armbrecht, G., Dietzel, R., Brix, S., Henriksen, K., and Karsdal, M.A. (2018). Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194458"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.tranon.2018.02.005","article-title":"Tumstatin, a Matrikine Derived from Collagen Type IV\u03b13, is Elevated in Serum from Patients with Non-Small Cell Lung Cancer","volume":"11","author":"Nielsen","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1002\/cam4.1692","article-title":"Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders","volume":"7","author":"Jensen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/ijc.31627","article-title":"High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts","volume":"143","author":"Lipton","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40425-018-0474-z","article-title":"Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients","volume":"6","author":"Jensen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/15384047.2018.1550571","article-title":"Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer","volume":"20","author":"Willumsen","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00432-018-2799-x","article-title":"Non-invasive profiling of protease-specific elastin turnover in lung cancer: Biomarker potential","volume":"145","author":"Kehlet","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tranon.2018.11.004","article-title":"Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (\u03b1-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders","volume":"12","author":"Nielsen","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_129","first-page":"38","article-title":"A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis","volume":"17","author":"Leeming","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13046-019-1110-6","article-title":"Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology","volume":"38","author":"Nissen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tranon.2019.02.004","article-title":"Matrix Metalloprotease Generated Fragments of Type VI Collagen Have Serum Biomarker Potential in Cancer\u2014A Proof of Concept Study","volume":"12","author":"Willumsen","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/gerona\/gly163","article-title":"Bone and Soft Tissue Turnover in Relation to All-cause Mortality in Postmenopausal Women","volume":"74","author":"Bager","year":"2019","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Banys-Paluchowski, M., Loibl, S., Witzel, I., Mundhenke, C., Lederer, B., Solbach, C., Karn, T., Marm\u00e9, F., Nekljudova, V., and Schem, C. (2019). Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers, 11.","DOI":"10.1055\/s-0039-1687939"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.18632\/oncotarget.27332","article-title":"Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease","volume":"10","author":"Nissen","year":"2019","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"19761","DOI":"10.1038\/s41598-019-56268-3","article-title":"Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer","volume":"9","author":"Willumsen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_136","unstructured":"Karsdal, M.A. (2019). Biochemistry of Collagens, Laminins Elastin, Elsevier."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1038\/s41598-020-62474-1","article-title":"A Fragment of Collagen Type VI alpha-3 chain is Elevated in Serum from Patients with Gastrointestinal Disorders","volume":"10","author":"Nielsen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1002\/ijc.32751","article-title":"Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer","volume":"146","author":"Chen","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Thorlacius-Ussing, J., Manon-Jensen, T., Sun, S., Leeming, D.J., Sand, J.M., Karsdal, M., and Willumsen, N. (2020). Serum Type XIX Collagen is Significantly Elevated in Non-Small Cell Lung Cancer: A Preliminary Study on Biomarker Potential. Cancers, 12.","DOI":"10.3390\/cancers12061510"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Jensen, C., Sinkeviciute, D., Madsen, D.H., \u00d6nnerfjord, P., Hansen, M., Schmidt, H., Karsdal, M.A., Svane, I.M., and Willumsen, N. (2020). Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. Cancers, 12.","DOI":"10.3390\/cancers12102786"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e001193","DOI":"10.1136\/jitc-2020-001193","article-title":"Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma","volume":"8","author":"Hurkmans","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/JHC.S275008","article-title":"Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma\u2014A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients","volume":"7","author":"Jensen","year":"2020","journal-title":"J. Hepatocell. Carcinoma."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41598-020-79608-0","article-title":"Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab","volume":"11","author":"Nissen","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"T\u00fcrl\u00fc, C., Willumsen, N., Marando, D., Schjerling, P., Biskup, E., Hannibal, J., Jorgensen, L.N., and \u00c5gren, M.S. (2021). A Human Cellular Model for Colorectal Anastomotic Repair: The Effect of Localization and Transforming Growth Factor-\u03b21 Treatment on Collagen Deposition and Biomarkers. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041616"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e62927","DOI":"10.7554\/eLife.62927","article-title":"Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction","volume":"10","author":"Ramos","year":"2021","journal-title":"Elife"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.33551","article-title":"Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma","volume":"149","author":"Nissen","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41523-021-00313-w","article-title":"Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer","volume":"7","author":"Liu","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"114272","DOI":"10.1016\/j.jpba.2021.114272","article-title":"Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients","volume":"204","author":"Willumsen","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-021-02133-z","article-title":"Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy","volume":"40","author":"Jensen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinbiochem.2021.08.007","article-title":"Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes","volume":"97","author":"Karsdal","year":"2021","journal-title":"Clin. Biochem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awab166","article-title":"Plasma amyloid-\u03b2 ratios in autosomal dominant Alzheimer\u2019s disease: The influence of genotype","volume":"144","author":"Pannee","year":"2021","journal-title":"Brain"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.mbplus.2022.100101","article-title":"Uncovering mediators of collagen degradation in the tumor microenvironment","volume":"13","author":"Thorseth","year":"2022","journal-title":"Matrix Biol. Plus"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Nissen, N.I., Johansen, A.Z., Chen, I., Johansen, J.S., Pedersen, R.S., Hansen, C.P., Karsdal, M.A., and Willumsen, N. (2022). Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14030819"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00018-022-04226-0","article-title":"Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types","volume":"79","author":"Willumsen","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Thorlacius-Ussing, J., Jensen, C., Madsen, E.A., Nissen, N.I., Manon-Jensen, T., Chen, I.M., Johansen, J.S., Diab, H.M.H., J\u00f8rgensen, L.N., and Karsdal, M.A. (2022). Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084144"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Pedersen, R.S., Nissen, N.I., Jensen, C., Thorlacius-Ussing, J., Manon-Jensen, T., Olesen, M.L., Langholm, L.L., Diab, H.M.H., Jorgensen, L.N., and Hansen, C.P. (2022). Plasma Kallikrein-Activated TGF-\u03b2 Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibrogenesis. Biomolecules, 12.","DOI":"10.3390\/biom12091315"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Madsen, E.A., Thorlacius-Ussing, J., Nissen, N.I., Jensen, C., Chen, I.M., Johansen, J.S., Diab, H.M.H., J\u00f8rgensen, L.N., Hansen, C.P., and Karsdal, M.A. (2022). Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Cells, 11.","DOI":"10.3390\/cells11233763"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM197907053010104","article-title":"The biosynthesis of collagen and its disorders (first of two parts)","volume":"301","author":"Prockop","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM197907123010204","article-title":"The biosynthesis of collagen and its disorders (second of two parts)","volume":"301","author":"Prockop","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0076-6879(87)44170-0","article-title":"The collagens: An overview and update","volume":"144","author":"Miller","year":"1987","journal-title":"Methods Enzymol."},{"key":"ref_161","unstructured":"Gay, S., and Miller, E.J. (1978). Collagen in the Physiology and Pathology of Connective Tissue, Gustav Fischer."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: Wounds that do not heal-redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0039-1687908","article-title":"Tumors: Wounds That Do Not Heal\u2014A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting","volume":"45","author":"Dvorak","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"660609","DOI":"10.3389\/fcell.2021.660609","article-title":"Reconciling VEGF with VPF: The Importance of Increased Vascular Permeability for Stroma Formation in Tumors, Healing Wounds, and Chronic Inflammation","volume":"9","author":"Dvorak","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(86)90733-6","article-title":"The biology of platelet-derived growth factor","volume":"46","author":"Ross","year":"1986","journal-title":"Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2014-03-562538","article-title":"Paraneoplastic thrombocytosis: The secrets of tumor self-promotion","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.leukres.2014.07.006","article-title":"The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?","volume":"38","author":"Hasselbalch","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_170","first-page":"78","article-title":"Hyaluronic Acid in Inflammation and Tissue Regeneration","volume":"28","author":"Litwiniuk","year":"2016","journal-title":"Wounds"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Abatangelo, G., Vindigni, V., Avruscio, G., Pandis, L., and Brun, P. (2020). Hyaluronic Acid: Redefining Its Role. Cells, 9.","DOI":"10.3390\/cells9071743"},{"key":"ref_172","first-page":"9","article-title":"Myelofibrosis-Osteomyelosclerosis Syndrome\u2014Review of literature and histomorphology","volume":"Volume 16","author":"Burkhardt","year":"1974","journal-title":"Advances in the Biosciences, Dahlem Workshop on Myelofibrosis-Osteomyelosclerosis Syndrome"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","article-title":"Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Mesa","year":"2000","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0609.2004.00235.x","article-title":"Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression","volume":"72","author":"Panteli","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000086583","article-title":"Clinical correlation of bone marrow microvessel density in essential thrombocythemia","volume":"114","author":"Panteli","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2141.2007.06885.x","article-title":"Bone marrow microvessel density in chronic myeloproliferative disorders: A study of 115 patients with clinicopathological and molecular correlations","volume":"140","author":"Boveri","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2009.07726.x","article-title":"Angiogenesis and vascular endothelial growth factor-\/receptor expression in myeloproliferative neoplasms: Correlation with clinical parameters and JAK2-V617F mutational status","volume":"146","author":"Medinger","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_178","first-page":"233","article-title":"Patoanatomical features of the bone marrow","volume":"39","author":"Lennert","year":"1975","journal-title":"Clin. Haematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1985.tb07336.x","article-title":"Immuno-enzymatic detection of fibronectin in normal and pathological haematopoietic tissue","volume":"59","author":"Reilly","year":"1985","journal-title":"Br. J. Haematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1985.tb07465.x","article-title":"Endothelial cell proliferation in myelofibrosis","volume":"60","author":"Reilly","year":"1985","journal-title":"Br. J. Haematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/309804a0","article-title":"Cellular transformation by coordinated action of three peptide growth factors from human platelets","volume":"309","author":"Assoian","year":"1984","journal-title":"Nature"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/S0021-9258(18)61316-X","article-title":"Purification and properties of an endothelial cell growth factor from human platelets","volume":"262","author":"Miyazono","year":"1987","journal-title":"J. Biol. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2021012827","article-title":"The bone marrow niche from the inside out: How megakaryocytes are shaped by and shape hematopoiesis","volume":"139","author":"Stone","year":"2022","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"912060","DOI":"10.3389\/fonc.2022.912060","article-title":"Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche","volume":"12","author":"Zhan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2020.01540","article-title":"Regulation of the Bone Marrow Niche by Inflammation","volume":"11","author":"Mitroulis","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-017-2266-5","article-title":"Impact of inflammation on early hematopoiesis and the microenvironment","volume":"106","author":"Takizawa","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/hematology.2019000045","article-title":"Inflammatory bone marrow microenvironment","volume":"2019","author":"Schneider","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/leu.2016.114","article-title":"JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation","volume":"30","author":"Zhan","year":"2016","journal-title":"Leukemia"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F Megakaryocytes Promote Hematopoietic Stem\/Progenitor Cell Expansion in Mice through Thrombopoietin\/MPL Signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/stmcls\/sxac005","article-title":"JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm","volume":"40","author":"Lee","year":"2022","journal-title":"Stem Cells"},{"key":"ref_191","first-page":"47","article-title":"Sequential appearance of fibronectin and collagen in experimental granulation tissue","volume":"43","author":"Kurkinen","year":"1980","journal-title":"Lab. Invest."},{"key":"ref_192","unstructured":"Andreasen, A.P. (1958). Myelofibrosis, Munksgaard."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-57-1-73","article-title":"A clinical and pathological study of seventy cases of myelofibrosis","volume":"57","author":"Pitcock","year":"1962","journal-title":"Ann. Intern. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00000441-196206000-00001","article-title":"Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients","volume":"243","author":"Bouroncle","year":"1962","journal-title":"Am. J. Med. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/1097-0142(197710)40:4<1548::AID-CNCR2820400427>3.0.CO;2-U","article-title":"Chronic myelolytic leukemia versus idiopathic myelofibrosis: A diagnostic problem in bone marrow biopsies","volume":"40","author":"Buyssens","year":"1977","journal-title":"Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005792-197109000-00001","article-title":"The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome","volume":"50","author":"Ward","year":"1971","journal-title":"Medicine"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/00313028209092127","article-title":"Prognostic factors in myelofibrosis","volume":"14","author":"Manoharan","year":"1982","journal-title":"Pathology"},{"key":"ref_198","first-page":"593","article-title":"Progressive myelofibrosis in agnogenic myeloid metaplasia","volume":"107","author":"Lohman","year":"1983","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations--the Danish experience","volume":"88","author":"Madelung","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.26751","article-title":"The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Buhr","year":"2012","journal-title":"Haematologica"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0609.1984.tb00724.x","article-title":"Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis","volume":"33","author":"Manoharan","year":"1984","journal-title":"Scand. J. Haematol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V65.4.803.803","article-title":"Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly","volume":"65","author":"Wolf","year":"1985","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0609.1988.tb00812.x","article-title":"Ultrasonic characterization of splenic tissue in myelofibrosis: Further evidence for reversal of fibrosis with chemotherapy","volume":"40","author":"Manoharan","year":"1988","journal-title":"Eur. J. Haematol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0344-0338(88)80090-6","article-title":"Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients","volume":"183","author":"Thiele","year":"1988","journal-title":"Pathol. Res. Pract."},{"key":"ref_208","first-page":"617","article-title":"Die sogenannte prim\u00e4re (idiopathische) Osteomyelofibrose\/-sklerose (OMF) im Rahmen chronischer myeloproliferativer Erkrankungen. I. Initiale klinische und histologische Befunde bei 102 Patienten mit besonderer Ber\u00fccksichtigung der fr\u00fchen zellreichen und der fortgeschrittenen fibrosklerotischen Stadien [So-called primary (idiopathic) osteomyelofibrosis\/-sclerosis (OMF) within the scope of chronic myeloproliferative diseases. I. Initial clinical and histologic findings in 102 patients with special reference to early hyperplastic and advanced fibrosclerotic stages]","volume":"83","author":"Zankovich","year":"1988","journal-title":"Med. Klin."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0609.1991.tb01540.x","article-title":"A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis","volume":"46","author":"Hasselbalch","year":"1991","journal-title":"Eur. J. Haematol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2141.1979.tb03697.x","article-title":"Bone marrow fibre production in myelofibrosis: A quantitative study","volume":"42","author":"Bentley","year":"1979","journal-title":"Br. J. Haematol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)\u2014A clinicopathological study","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.15562","article-title":"What is pre-fibrotic myelofibrosis and how should it be managed in 2018?","volume":"183","author":"Ianotto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.15840","article-title":"Comments on pre-fibrotic myelofibrosis and how should it be managed","volume":"186","author":"Barbui","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1990.tb00357.x","article-title":"Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation","volume":"44","author":"Pereira","year":"1990","journal-title":"Eur. J. Haematol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/0002-9343(76)90573-8","article-title":"Spontaneous hematologic remission in agnogenic myeloid metaplasia","volume":"60","author":"Shreiner","year":"1976","journal-title":"Am. J. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0022-3476(81)80769-X","article-title":"Spontaneous resolution of severe childhood myelofibrosis","volume":"98","author":"Lau","year":"1981","journal-title":"J. Pediatr."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0360-3016(77)90112-2","article-title":"Splenic irradiation in myelofibrosis. Clinical findings and ferrokinetics","volume":"2","author":"Parmentier","year":"1977","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1978.tb01555.x","article-title":"Polycythaemia vera-transformation to myelofibrosis and subsequent reversal","volume":"20","author":"Pettit","year":"1978","journal-title":"Scand. J. Haematol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0308-2261(21)00078-3","article-title":"Patho-anatomical features of the spleen and liver","volume":"4","author":"Bandmann","year":"1975","journal-title":"Clin. Haematol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0609.1984.tb00671.x","article-title":"Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis","volume":"32","author":"Barosi","year":"1984","journal-title":"Scand. J. Haematol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000205163","article-title":"Spontaneous remission of agnogenic myeloid metaplasia in a splenectomized patient: A case report with erythrokinetic studies","volume":"83","author":"Shimizu","year":"1990","journal-title":"Acta Haematol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1002\/1097-0142(19811115)48:10<2198::AID-CNCR2820481014>3.0.CO;2-M","article-title":"Bone marrow transplantation for acute myelosclerosis","volume":"48","author":"Smith","year":"1981","journal-title":"Cancer"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V59.1.191.191","article-title":"Reversal of acute (\u201cmalignant\u201d) myelosclerosis by allogeneic bone marrow transplantation","volume":"59","author":"Wolf","year":"1982","journal-title":"Blood"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0140-6736(82)91769-X","article-title":"Bone-marrow transplantation for acute myelofibrosis","volume":"1","author":"Rozman","year":"1982","journal-title":"Lancet"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.1983.03330330067039","article-title":"Acute myelofibrosis. Treatment with allogeneic bone marrow transplantation","volume":"249","author":"Kroener","year":"1983","journal-title":"JAMA"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.1983.tb02045.x","article-title":"Reversal of marrow fibrosis in acute megakaryoblastic leukaemia after remission-induction and consolidation chemotherapy followed by bone marrow transplantation","volume":"53","author":"Mehta","year":"1983","journal-title":"Br. J. Haematol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.1989.tb06292.x","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"71","author":"Dokal","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Chatain, N., Koschmieder, S., and Jost, E. (2020). Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12082250"},{"key":"ref_237","first-page":"361","article-title":"Effect of alkylating agents on hematopoiesis in myelofibrosis. 4 case report","volume":"26","author":"Charbord","year":"1978","journal-title":"Nouv. Rev. Fr. Hematol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: A preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","article-title":"Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","volume":"28","author":"Pizzi","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"10","author":"Hasselbalch","year":"2017","journal-title":"Expert. Rev. Hematol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study","volume":"105","author":"Mikkelsen","year":"2020","journal-title":"Haematologica"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","article-title":"New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"Hemasphere"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000206081","article-title":"High-dose intravenous corticosteroid treatment in childhood idiopathic myelofibrosis","volume":"75","author":"Ozsoylu","year":"1986","journal-title":"Acta Haematol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.2830250215","article-title":"A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: Evidence of an autoimmune pathogenesis","volume":"25","author":"Hasselbalch","year":"1987","journal-title":"Am. J. Hematol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(88)91570-X","article-title":"High-dose intravenous methylprednisolone for idiopathic myelofibrosis","volume":"1","author":"Ozsoylu","year":"1988","journal-title":"Lancet"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2141.1988.tb02503.x","article-title":"High dose intravenous methylprednisolone for idiopathic myelofibrosis","volume":"70","author":"Ozsoylu","year":"1988","journal-title":"Br. J. Haematol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000204592","article-title":"Myelofibrosis and systemic lupus erythematosus: Reversal of fibrosis with high-dose corticosteroid therapy","volume":"88","author":"Inoue","year":"1992","journal-title":"Acta Haematol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/10428190310001597982","article-title":"Autoimmune myelofibrosis: Report of three cases and review of the literature","volume":"45","author":"Rizzi","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-199405000-00003","article-title":"Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus","volume":"73","author":"Paquette","year":"1994","journal-title":"Medicine"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2016-03-705012","article-title":"Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis","volume":"128","author":"Masarova","year":"2016","journal-title":"Blood"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1979.tb05843.x","article-title":"Biochemical and histological analysis of bone marrow collagen in myelofibrosis","volume":"41","author":"Charron","year":"1979","journal-title":"Br. J. Haematol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2141.1981.tb02714.x","article-title":"Collagen heterogeneity in normal human bone marrow","volume":"48","author":"Bentley","year":"1981","journal-title":"Br. J. Haematol."},{"key":"ref_255","unstructured":"Berk, P.D., Castro-Malaspina, H., and Wasserman, L.R. (1984). Myelofibrosis and the Biology of Connective Tissue, Alan R, Liss, Inc."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1749-6632.1985.tb51172.x","article-title":"Collagen fibrillogenesis in human skin","volume":"460","author":"Fleischmajer","year":"1985","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(63)80130-4","article-title":"Capillarization of hepatic sinusoids in man","volume":"44","author":"Schaffner","year":"1963","journal-title":"Gastroenterology"},{"key":"ref_258","first-page":"216","article-title":"Radioimmunoassays for monitoring connective tissue metabolism","volume":"10","author":"Risteli","year":"1986","journal-title":"Rheumatol"},{"key":"ref_259","unstructured":"Rojkind, M. (1990). Focus on Connective Tissue in Health and Disease, CRC Press Inc."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.bi.47.070178.001021","article-title":"Biosynthesis of procollagen","volume":"47","author":"Fessler","year":"1978","journal-title":"Annu. Rev. Biochem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF00598910","article-title":"The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis","volume":"8","author":"Vellenga","year":"1983","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.1989.tb07644.x","article-title":"Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia","volume":"72","author":"Barosi","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2362.1979.tb00912.x","article-title":"Radioimmunoassay for type III procollagen peptide and its application to human liver disease","volume":"9","author":"Rohde","year":"1979","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-8981(82)90317-5","article-title":"Heterogeneity of the antigens related to the aminoterminal propeptide of type III procollagen in human serum","volume":"124","author":"Risteli","year":"1982","journal-title":"Clin. Chim. Acta"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/art.1780290503","article-title":"Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions","volume":"29","author":"Bentsen","year":"1986","journal-title":"Arthritis Rheum."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.47.2.116","article-title":"Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: Relation to clinical and serological parameters of inflammation during 8 and 24 months\u2019 treatment with levamisole, penicillamine, or azathioprine","volume":"47","author":"Bentsen","year":"1988","journal-title":"Ann. Rheum. Dis."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00541343","article-title":"The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis","volume":"8","author":"Saxne","year":"1988","journal-title":"Rheumatol. Int."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1600-0609.1987.tb01460.x","article-title":"Serum procollagen-III-peptide as a marker for primary myelofibrosis: Effect of anthracyclin","volume":"39","author":"Parmentier","year":"1987","journal-title":"Eur. J. Haematol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0168-8278(88)80025-4","article-title":"Is the aminoterminal propeptide of type III procollagen degraded in the liver? A study of type III procollagen peptide in serum during liver transplantation in pigs","volume":"6","author":"Bentsen","year":"1988","journal-title":"J. Hepatol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0016-5085(83)90308-6","article-title":"Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease","volume":"85","author":"Risteli","year":"1983","journal-title":"Gastroenterology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0676.1987.tb00365.x","article-title":"Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse. Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan","volume":"7","author":"Bentsen","year":"1987","journal-title":"Liver"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1034\/j.1600-0609.2003.00134.x","article-title":"Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: Correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism","volume":"71","author":"Jensen","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1600-0609.2002.01732.x","article-title":"Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera","volume":"69","author":"Jensen","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.34356","article-title":"Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer","volume":"152","author":"Christensen","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1034\/j.1600-0609.2003.00096.x","article-title":"Elevated plasma levels of TIMP-1 correlate with plasma suPAR\/uPA in patients with chronic myeloproliferative disorders","volume":"71","author":"Jensen","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0145-2126(94)90044-2","article-title":"Serum laminin P1 in idiopathic myelofibrosis and related diseases","volume":"18","author":"Hasselbalch","year":"1994","journal-title":"Leuk. Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2362.1985.tb00156.x","article-title":"Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease","volume":"15","author":"Risteli","year":"1985","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0676.1985.tb00253.x","article-title":"Early alcoholic liver injury: Changes of the Disse space in acinar zone 3","volume":"5","author":"Horn","year":"1985","journal-title":"Liver"},{"key":"ref_279","unstructured":"H\u00f8rslev-Petersen, K. (1990). Circulating Extracellular Matrix Components as Markers for Connective Tissue Response to Inflammation. A Clinical and Experimental Study with Special Emphasis on Serum Aminoterminal Type III Procollagen Peptide in Rheumatic Diseases. [Ph.D. Thesis, L\u00e6geforeningens Forlag]."},{"key":"ref_280","first-page":"87","article-title":"Recent advances in the biochemistry of hyaluronic acid in cartilage","volume":"54","author":"Mason","year":"1981","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ard.44.2.83","article-title":"Circulating hyaluronate in rheumatoid arthritis: Relationship to inflammatory activity and the effect of corticosteroid therapy","volume":"44","year":"1985","journal-title":"Ann. Rheum. Dis."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.44.9.614","article-title":"Raised serum hyaluronate levels in scleroderma: An effect of growth factor induced activation of connective tissue cells?","volume":"44","author":"Feltelius","year":"1985","journal-title":"Ann. Rheum. Dis."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hep.1840050420","article-title":"Increased serum levels of hyaluronate in liver disease","volume":"5","author":"Nyberg","year":"1985","journal-title":"Hepatology"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-92-6-857","article-title":"The pathogenesis of myelofibrosis in myeloproliferative disorders","volume":"92","author":"Groopman","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.V57.4.781.781","article-title":"Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts","volume":"57","author":"Rabellino","year":"1981","journal-title":"Blood"},{"key":"ref_286","first-page":"221","article-title":"Pathophysiological mechanisms operating in the development of myelofibrosis: Role of megakaryocytes","volume":"24","author":"Moore","year":"1982","journal-title":"Nouv. Rev. Fr. Hematol."},{"key":"ref_287","unstructured":"Berk, P.D., Castro-Malaspina, H., and Wasseman, L.R. (1984). Myelofibrosis and the Biology of Connective Tissue, Alan R. Liss, Inc."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/bj2000415","article-title":"Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit","volume":"200","author":"Fraser","year":"1981","journal-title":"Biochem. J."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00238296","article-title":"Tissue uptake of circulating hyaluronic acid. A whole body autoradiographic study","volume":"233","author":"Fraser","year":"1983","journal-title":"Cell Tissue Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-4827(83)90458-5","article-title":"Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver","volume":"144","author":"Eriksson","year":"1983","journal-title":"Exp. Cell Res."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-1681.1984.tb00235.x","article-title":"Elimination of hyaluronic acid from the blood stream in the human","volume":"11","author":"Fraser","year":"1984","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1042\/bj2560153","article-title":"Uptake and degradation of hyaluronan in lymphatic tissue","volume":"256","author":"Fraser","year":"1988","journal-title":"Biochem. J."},{"key":"ref_293","first-page":"195","article-title":"On the origin of hylaronate in blood","volume":"2","author":"Laurent","year":"1981","journal-title":"Biochem. Int."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V61.2.257.257","article-title":"Glycosaminoglycans in human neutrophils and leukemic myeloblasts: Ultrastructural, cytochemical, immunologic, and biochemical characterization","volume":"61","author":"Parmley","year":"1983","journal-title":"Blood"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood.V73.7.1821.1821","article-title":"Proteoglycan synthesis by hematopoietic progenitor cells","volume":"73","author":"Minguell","year":"1989","journal-title":"Blood"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.17219\/acem\/104531","article-title":"Fibronectin and its soluble EDA-FN isoform as biomarkers for inflammation and sepsis","volume":"28","author":"Adamik","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1084\/jem.20181074","article-title":"EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis","volume":"216","author":"Malara","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"987643","DOI":"10.3389\/fonc.2022.987643","article-title":"Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression","volume":"12","author":"Malara","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2141.2002.03874.x","article-title":"Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis","volume":"119","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190500126463","article-title":"Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia","volume":"46","author":"Wang","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1182\/blood-2018-99-117122","article-title":"Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms","volume":"132","author":"Skov","year":"2018","journal-title":"Blood"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ejh.12332","article-title":"Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state","volume":"93","author":"Andersen","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.leukres.2014.04.002","article-title":"Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat","volume":"38","author":"Andersen","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/17843286.2019.1659467","article-title":"Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms","volume":"76","author":"Gulin","year":"2021","journal-title":"Acta Clin. Belg."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10245332.2018.1498157","article-title":"Serum chitotriosidase: A circulating biomarker in polycythemia vera","volume":"23","author":"Krecak","year":"2018","journal-title":"Hematology"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Verstovsek, S., Foltz, L., Gupta, V., Hasserjian, R., Manshouri, T., Mascarenhas, J., Mesa, R., Pozdnyakova, O., Ritchie, E., and Veletic, I. (2023). Safety and efficacy of zinpentraxin as monotherapy or in combination with ruxolitinib in myelofibrosis. A stage I of a Phase II trial. Haematologica, epub ahead of print.","DOI":"10.3324\/haematol.2022.282411"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200091","article-title":"Endotrophin, a Collagen VI Formation\u2013Derived Peptide, in Heart Failure","volume":"1","author":"Chirinos","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: Contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jchf.2015.11.013","article-title":"Inflammation in Heart Failure with Preserved Ejection Fraction: Time to put out the Fire","volume":"4","author":"Shah","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure with Preserved Ejection Fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"e10865","DOI":"10.15252\/emmm.201910865","article-title":"Targeting cardiac fibrosis in heart failure with preserved ejection fraction: Mirage or miracle?","volume":"12","author":"Sweeney","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure with Preserved Ejection Fraction Paradigm Revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ. Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"6687096","DOI":"10.1155\/2021\/6687096","article-title":"NETosis as a Pathogenic Factor for Heart Failure","volume":"2021","author":"Ling","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1057349","DOI":"10.3389\/fendo.2022.1057349","article-title":"A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF","volume":"13","author":"Troncoso","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"e85974","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI Insight."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","article-title":"Collagen density regulates the activity of tumor-infiltrating T cells","volume":"7","author":"Kuczek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_320","first-page":"225","article-title":"Therapeutic Cancer Vaccination with a Peptide Derived from the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients with CALR-Mutant Chronic Myeloproliferative Neoplasms","volume":"11","author":"Grauslund","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1117466","DOI":"10.3389\/fimmu.2023.1117466","article-title":"An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial","volume":"14","author":"Grauslund","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"ref_323","first-page":"5ra13","article-title":"Serum amyloid P inhibits fibrosis through Fc\u03b3R-dependent monocyte-macrophage regulation in vivo","volume":"1","author":"Lin","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-007-9126-7","article-title":"Pentraxins in innate immunsity: From C-reactive protein to the long pentraxin PTX3","volume":"28","author":"Mantovani","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3389\/fimmu.2018.02328","article-title":"The Development of Serum Amyloid P as a Possible Therapeutic","volume":"9","author":"Pilling","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.15528","article-title":"Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis","volume":"185","author":"Veletic","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_327","doi-asserted-by":"crossref","unstructured":"Murray, L.A., Rosada, R., Moreira, A.P., Joshi, A., Kramer, M.S., Hesson, D.P., Argentieri, R.L., Mathai, S., Gulati, M., and Herzog, E.L. (2010). Serum amyloid P therapeutically attenuates. murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009683"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"e87446","DOI":"10.1172\/jci.insight.87446","article-title":"Pentraxin-2 suppresses c-Jun\/AP-1 signaling to inhibit progressive fibrotic disease","volume":"1","author":"Nakagawa","year":"2016","journal-title":"JCI Insight"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of Recombinant Human Pentraxin 2 vs. Placebo on Change in Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial","volume":"319","author":"Raghu","year":"2018","journal-title":"JAMA"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S2213-2600(19)30172-9","article-title":"Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: An open-label extension study","volume":"7","author":"Raghu","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-022-02047-0","article-title":"Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): An open-label extension study","volume":"23","author":"Raghu","year":"2022","journal-title":"Respir. Res."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: Old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","article-title":"Colchicine Attenuates Inflammation beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy","volume":"142","author":"Opstal","year":"2020","journal-title":"Circulation"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Celermajer","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: Pushing the envelope","volume":"62","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/CRD.0000000000000056","article-title":"The cardiovascular effects of colchicine: A comprehensive review","volume":"23","author":"Casanova","year":"2015","journal-title":"Cardiol. Rev."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14748\/bmr.v28.4456","article-title":"Colchicine, Inflammation and Fibrosis in Cardiovascular Disease: Merging Three Classical Tales","volume":"28","author":"Chaldakov","year":"2017","journal-title":"Biomed. Rev."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","article-title":"Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview","volume":"41","author":"Nidorf","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"e13424","DOI":"10.1111\/eci.13424","article-title":"Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial","volume":"50","author":"Kraler","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_344","doi-asserted-by":"crossref","unstructured":"Fiolet, A.T.L., Silvis, M.J.M., Opstal, T.S.J., Bax, W.A., van der Horst, F.A.L., Mosterd, A., de Kleijn, D., and Cornel, J.H. (2020). Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237665"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11886-021-01560-w","article-title":"Colchicine in the Management of Acute and Chronic Coronary Artery Disease","volume":"23","author":"Bouabdallaoui","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and metaanalysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjmed.2021.01.019","article-title":"The Use of Colchicine in Cardiovascular Diseases: A Systematic Review","volume":"134","author":"Siak","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"e018993","DOI":"10.1161\/JAHA.120.018993","article-title":"Colchicine inhibits neutrophil extracellular trap Formation in patients with acute coronary syndrome after percutaneous coronary intervention","volume":"10","author":"Vaidya","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_350","doi-asserted-by":"crossref","unstructured":"Cantrell, M.S., Soto-Avellaneda, A., Wall, J.D., Ajeti, A.D., Morrison, B.E., Warner, L.R., and McDougal, O.M. (2021). Repurposing Drugs to Treat Heart and Brain Illness. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060573"},{"key":"ref_351","first-page":"61","article-title":"Colchicine in Cardiovascular Disease: In-Depth Review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"940465","DOI":"10.3389\/fmolb.2022.940465","article-title":"Editorial: New Insights into Oxidative Stress and Inflammation in the Pathophysiology and Treatment of Cardiovascular Diseases","volume":"9","author":"Becatti","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2011.03.013","article-title":"High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis","volume":"35","author":"Hasselbalch","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H.C., Skov, V., Larsen, T.S., Thomassen, M., Riley, C.H., Jensen, M.K., Bjerrum, O.W., and Kruse, T.A. (2014). Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085567"},{"key":"ref_359","doi-asserted-by":"crossref","unstructured":"Skov, V., Burton, M., Thomassen, M., Larsen, T.S., Riley, C.H., Madelung, A.B., Kj\u00e6r, L., Bondo, H., Stamp, I., and Ehinger, M. (2016). A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161570"},{"key":"ref_360","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H.C., Thomassen, M., Riley, C.H., Kj\u00e6r, L., Larsen, T.S., Jensen, M.K., Bjerrum, O.W., Kruse, T.A., and Skov, V. (2014). Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS ONE, 9, Erratum in: PLoS ONE 2015, 10, e0118049.","DOI":"10.1371\/journal.pone.0118049"},{"key":"ref_361","doi-asserted-by":"crossref","unstructured":"Skov, V., Thomassen, M., Kjaer, L., Ellervik, C., Larsen, M.K., Knudsen, T.A., Kruse, T.A., and Hasselbalch, H.C. (2022). Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270669"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1182\/blood-2022-157906","article-title":"Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms","volume":"140","author":"Skov","year":"2022","journal-title":"Blood"},{"key":"ref_363","unstructured":"Skov, V., Thomassen, M., Kjaer, L., Larsen, M.K., Knudsen, T.A., Ellervik, C., Junker, P., Kruse, T.A., and Hasselbalch, H.C. (2022, January 27\u201328). Transcriptional Profiling of Extracellular Matrix-Related Genes in Peripheral Blood from Patients with Polycythemia Vera and Related Neoplasms. Impact of Interferon-Alpha2. Poster ASH. Proceedings of the 14th International Congress on Myeloproliferative Neoplasms Program Guide, New York, NY, USA."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood-2019-131698","article-title":"Significantly upregulated thrombo-inflammatory genes are normoregulated or significantly downregulated during treatment with interferon-alpha2 in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"134","author":"Skov","year":"2019","journal-title":"Blood"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_366","doi-asserted-by":"crossref","unstructured":"Massarenti, L., Knudsen, T.A., Enevold, C., Skov, V., Kj\u00e6r, L., Larsen, M.K., Nielsen, C.H., and Hasselbalch, H.C. (2023). Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms. Br. J. Haematol., in press.","DOI":"10.1111\/bjh.18845"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.4359","article-title":"Neutrophil extracellular traps promote differentiation and function of fibroblasts","volume":"233","author":"Chrysanthopoulou","year":"2014","journal-title":"J. Pathol."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1083\/jcb.62.2.390","article-title":"Effects of antimicrotubular agents on the secretion of collagen. A biochemical and morphological study","volume":"62","author":"Ehrlich","year":"1974","journal-title":"J. Cell Biol."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.1780140602","article-title":"Effects of colchicine on collagenase in cultures of rheumatoid synovium","volume":"14","author":"Harris","year":"1971","journal-title":"Arthritis Rheum."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1164\/ajrccm\/137.1.181","article-title":"Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach ot the fibrotic disorders","volume":"137","author":"Rennard","year":"1988","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.103.1.101","article-title":"Colchicine in the treatment of pulmonary fibrosis","volume":"103","author":"Peters","year":"1993","journal-title":"Chest"},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/PL00007555","article-title":"Antiinflammatory and antifibrotic properties of colchicine: Implications for idiopathic pulmonary fibrosis","volume":"175","author":"Entzian","year":"1997","journal-title":"Lung"},{"key":"ref_373","first-page":"CD003134","article-title":"Immunomodulatory agents for idiopathic pulmonary fibrosis","volume":"3","author":"Davies","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"648090","DOI":"10.1155\/2015\/648090","article-title":"The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.redox.2021.101895","article-title":"Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study","volume":"41","author":"Hasselbalch","year":"2021","journal-title":"Redox Biol."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/bloodadvances.2019000967","article-title":"N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm","volume":"4","author":"Craver","year":"2020","journal-title":"Blood Adv."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMe058210","article-title":"Antioxidant therapy for idiopathic pulmonary fibrosis","volume":"353","author":"Hunninghake","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"e3629","DOI":"10.1097\/MD.0000000000003629","article-title":"Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine"},{"key":"ref_381","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez, F.J., de Andrade, J.A., Anstrom, K.J., King, T.E., and Raghu, G. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 370, 2093\u20132101.","DOI":"10.1056\/NEJMoa1401739"},{"key":"ref_382","doi-asserted-by":"crossref","unstructured":"Podolanczuk, A.J., Kim, J.S., Cooper, C.B., Lasky, J.A., Murray, S., Oldham, J.M., Raghu, G., Flaherty, K.R., Spino, C., and Noth, I. (2022). Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-02281-8"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0609.1978.tb00381.x","article-title":"Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man","volume":"21","author":"Pedersen","year":"1978","journal-title":"Scand. J. Haematol."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Caudrillier","year":"2017","journal-title":"Nature"},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12015-017-9747-z","article-title":"Lung as a Niche for Hematopoietic Progenitors","volume":"13","author":"Borges","year":"2017","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2019-123994","article-title":"Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1low Mutation","volume":"134","author":"Bacci","year":"2019","journal-title":"Blood"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"15640","DOI":"10.1038\/s41598-020-72768-z","article-title":"A prospective study of lung disease in a cohort of early rheumatoid arthritis patients","volume":"10","author":"Luburich","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_389","doi-asserted-by":"crossref","unstructured":"Florescu, A., Gherghina, F.L., Mu\u0219etescu, A.E., P\u0103dureanu, V., Ro\u0219u, A., Florescu, M.M., Criveanu, C., Florescu, L.-M., and Bobirc\u0103, A. (2022). Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease\u2014A Narrative Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061367"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"rkad023","DOI":"10.1093\/rap\/rkad023","article-title":"Are genes the missing link to detect and prognosticate RA-ILD?","volume":"7","author":"Vermant","year":"2023","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.eclinm.2020.100295","article-title":"Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study","volume":"21","author":"Pedersen","year":"2020","journal-title":"Eclinicalmedicine"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"Pravastatin or Atorvastatin, I. Infection Therapy-Thrombolysis in Myocardial Infarction, C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_393","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"101088","DOI":"10.1016\/j.redox.2018.101088","article-title":"Statin treatment, oxidative stress and inflammation in a Danish population","volume":"21","author":"Hasselbalch","year":"2019","journal-title":"Redox Biol."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/138945007779940133","article-title":"The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders","volume":"8","author":"Hasselbalch","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"ref_398","first-page":"20","article-title":"A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate","volume":"6","author":"Kallenbach","year":"2016","journal-title":"Leuk. Res. Rep."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12103","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","volume":"160","author":"Griner","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2014.06.013","article-title":"Novel prospects of statins a therapeutic agents in cancer","volume":"88","author":"Pisanti","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_401","first-page":"576","article-title":"Statin use and reduced cancer-related mortality","volume":"368","author":"Nielsen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms\u2014A Danish nationwide case-control study","volume":"7","author":"Kristensen","year":"2023","journal-title":"Blood Adv."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.tips.2018.07.006","article-title":"Metformin as an Anticancer Agent","volume":"39","author":"Vancura","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s43556-022-00108-w","article-title":"Metformin in therapeutic applications in human diseases: Its mechanism of action and clinical study","volume":"3","author":"Du","year":"2022","journal-title":"Mol. Biomed."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1515\/jbcpp-2022-0252","article-title":"Metformin: New applications for an old drug","volume":"34","author":"Naseri","year":"2022","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_406","doi-asserted-by":"crossref","unstructured":"Lan, W.-H., Lin, T.-Y., Yeh, J.-A., Feng, C.-L., Hsu, J.-T., Lin, H.-J., Kuo, C.-J., and Lai, C.-H. (2022). Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214163"},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"e31635","DOI":"10.1097\/MD.0000000000031635","article-title":"Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review","volume":"101","author":"Feng","year":"2022","journal-title":"Medicine"},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1021\/jacs.0c00650","article-title":"Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy","volume":"142","author":"Han","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1182\/blood-2022-165252","article-title":"Neutrophil-to-Lymphocyte Ratio as a Predictor of All-Cause Mortality in the General Population and in Patients with Myeloproliferative Neoplasms","volume":"140","author":"Larsen","year":"2022","journal-title":"Blood"},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1182\/blood-2022-157668","article-title":"Metformin Use and the Risk of Myeloproliferative Neoplasms in a Danish Population Based Cohort","volume":"140","author":"Kristensen","year":"2022","journal-title":"Blood"},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/s41375-021-01159-8","article-title":"Early detection of myeloproliferative neoplasms in a Danish general population study","volume":"35","author":"Cordua","year":"2021","journal-title":"Leukemia"},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49,488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2014A Common Pathway to Organ Injury and Failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: Burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"1005666","DOI":"10.3389\/frhem.2022.1005666","article-title":"Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report","volume":"1","author":"Egyed","year":"2022","journal-title":"Front. Hematol."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis\u2014Their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ajpath.2015.01.029","article-title":"Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer","volume":"185","author":"Brisson","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/labinvest.2008.31","article-title":"The fibromatosis signature defines a robust stromal response in breast carcinoma","volume":"88","author":"Beck","year":"2008","journal-title":"Lab. Invest."},{"key":"ref_420","first-page":"90","article-title":"A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy","volume":"3","author":"Nobre","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3892\/ijo.2021.5217","article-title":"Collagen type VI-\u03b11 and 2 repress the proliferation, migration and invasion of bladder cancer cells","volume":"59","author":"Piao","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Carstens","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"e146987","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1SMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","article-title":"Artificial intelligence-based morphological fingerprinting of megakaryocytes: A new tool for assessing disease in MPN patients","volume":"4","author":"Sirinukunwattana","year":"2020","journal-title":"Blood Adv."},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41375-022-01773-0","article-title":"Continuous Indexing of Fibrosis (CIF): Improving the assessment and classification of MPN patients","volume":"37","author":"Ryou","year":"2023","journal-title":"Leukemia"},{"key":"ref_428","doi-asserted-by":"crossref","unstructured":"Balduini, A., Badalucco, S., Pugliano, M.T., Baev, D., De Silvestri, A., Cattaneo, M., Rosti, V., and Barosi, G. (2011). In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: Distinct patterns in the different clinical phenotypes. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021015"},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"1090658","DOI":"10.3389\/fonc.2022.1090658","article-title":"Editorial: Megakaryocytes as regulators of tumor microenvironments","volume":"12","author":"Migliaccio","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"906698","DOI":"10.3389\/fonc.2022.906698","article-title":"Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis","volume":"12","author":"Varricchio","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000527284","article-title":"Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype","volume":"146","author":"Barosi","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_432","first-page":"725","article-title":"Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms","volume":"37","author":"Barosi","year":"2023","journal-title":"Challenges and perspectives. Leukemia"},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"100197","DOI":"10.1016\/j.rpth.2023.100197","article-title":"Inside-to-outside and back to the future of megakaryopoiesis","volume":"7","author":"Miguel","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_434","doi-asserted-by":"crossref","unstructured":"Barosi, G., Rosti, V., Bonetti, E., Campanelli, R., Carolei, A., Catarsi, P., Isgr\u00f2, A.M., Lupo, L., Massa, M., and Poletto, V. (2012). Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035631"},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.ircmb.2021.07.001","article-title":"Bone marrow microenvironment of MPN cells","volume":"365","author":"Malara","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1038\/bcj.2017.6","article-title":"The role of the extracellular matrix in primary myelofibrosis","volume":"7","author":"Leiva","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: The lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jcb.10413","article-title":"Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell","volume":"88","author":"Kagan","year":"2003","journal-title":"J. Cell Biochem."},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_440","first-page":"23","article-title":"Lysyl oxidase inhibition in primary myelofibrosis: A Renewed strategy","volume":"1","author":"Piasecki","year":"2020","journal-title":"Arch. Stem Cell Ther."},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice","volume":"110","author":"Leiva","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bjh.14501","article-title":"A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41467-023-37175-8","article-title":"Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies","volume":"14","author":"Xu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and clinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_446","doi-asserted-by":"crossref","unstructured":"Yao, Y., Findlay, A., Stolp, J., Rayner, B., Ask, K., and Jarolimek, W. (2022). Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.22541\/au.163847931.19877269\/v1"},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood"},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood-2015-02-629667","article-title":"Lysyl oxidase is associated with increased thrombosis and platelet reactivity","volume":"127","author":"Matsuura","year":"2016","journal-title":"Blood"},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.25008","article-title":"The role of extracellular matrix stiffness in megakaryocyte and platelet development and function","volume":"93","author":"Leiva","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"24103","DOI":"10.1074\/jbc.M709897200","article-title":"Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascularsmooth muscle cells","volume":"283","author":"Lucero","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_452","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H., Skov, V., Kj\u00e6r, L., Larsen, M.K., Knudsen, T.A., Lucijani\u0107, M., and Kusec, R. (2022). Recombinant Interferon-\u03b2 in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14225495"},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.sla.0000261460.07110.f2","article-title":"Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related receptors","volume":"246","author":"Vitale","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_454","first-page":"1237","article-title":"Synergistic antitumor effect of interferon-\u00df with gemcitabine in interferon-\u03b1-non-responsive pancreatic cancer cells","volume":"38","author":"Yomimaru","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jcmm.12200","article-title":"Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells","volume":"18","author":"Booy","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/jir.2014.0157","article-title":"Potentials of interferon therapy in the treatment of pancreatic cancer","volume":"35","author":"Booy","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_457","doi-asserted-by":"crossref","unstructured":"Blaauboer, A., Booy, S., van Koetsveld, P.M., Karels, B., Dogan, F., van Zwienen, S., van Eijck, C.H.J., and Hofland, L.J. (2020). Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07420-0"},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"951019","DOI":"10.3389\/fonc.2022.951019","article-title":"The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/ijo.2022.5387","article-title":"Immunomodulatory antitumor effect of interferon-beta combined with gemcitabine in pancreatic cancer","volume":"61","author":"Blaauboer","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"13792","DOI":"10.1073\/pnas.1713728114","article-title":"Interferon-beta represses cancer stem cell properties in triple-negative breast cancer","volume":"114","author":"Doherty","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-019-1136-x","article-title":"The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer","volume":"21","author":"Doherty","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_462","doi-asserted-by":"crossref","unstructured":"Aric\u00f2, E., Castiello, L., Capone, I., Gabriele, L., and Belardelli, F. (2019). Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers, 11.","DOI":"10.3390\/cancers11121943"},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.4049\/jimmunol.1900789","article-title":"Collagen Density Modulates the Immunosuppressive Functions of Macrophages","volume":"205","author":"Larsen","year":"2020","journal-title":"J. Immunol."},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"733561","DOI":"10.3389\/fimmu.2021.733561","article-title":"Collagen Fragments Produced in Cancer Mediate T Cell Suppression through Leukocyte-Associated Immunoglobulin-like Receptor 1","volume":"12","author":"Vijver","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc22-0852","article-title":"Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort","volume":"45","author":"Tougaard","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:42:14Z","timestamp":1760128934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":465,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174323"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174323","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}